MPT0G211 is a highly selective HDAC6 inhibitor, with comprehensive IP protection. MPT0G211 is mainly focused on multiple myelomabrain tumor indications. For IND package, we have completed CMC in drug substance, CMC in drug product, ADME,most preclinical toxicology studies, only the 28-days repeated dose toxicology study in dog is left. Once the 28-day repeated dose toxicology study in dog is completed, the IND package will be filed in the United StatesTaiwan in Q2 2022.

To train neurosurgery internsincrease their confidencesurgical skills, we employed 3D printing, mold design,casting technology to develop medical simulators. The simulators allow students to adjust the angle of the head based on the location of the angioma (brain tumor), perform a craniotomy, move the soft tissue of the brain aside using forceps, locate the angioma (brain tumor),clip the angioma (remove the brain tumor) using medical instruments,complete the entire training while artificial blood is flowing through the simulator.